Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice.
Terasaki M , Nagashima M , Nohtomi K , Kohashi K , Tomoyasu M , Sinmura K , Nogi Y , Katayama Y , Sato K , Itoh F , Watanabe T , Hirano T 
PLoS One.2013 ; 8(8):e70933.
PubMedで表示
Google翻訳で開く
Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan.
(372view , 0users)
Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe (-/-)) mice. It remains to be seen, however, whether this effect stems from increased levels of the two active incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
PMID: 23967137 [PubMed - in process]
PMID: 23967137 [PubMed - in process]
関連論文
- Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.
- Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
- [Review] Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
- Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein e-null mice.